Infection risk with JAK inhibitors in dermatoses: a meta-analysis.

Autor: Ireland PA; Prince of Wales Hospital, Randwick, NSW, Australia.; University of new South Wales, Randwick, NSW, Australia., Verheyden M; University of Sydney, Camperdown, NSW, Australia.; John Hunter Hospital, Newcastle, NSW, Australia., Jansson N; Gold Coast University Hospital, Gold Coast, QLD, Australia., Sebaratnam D; University of new South Wales, Randwick, NSW, Australia.; Liverpool Hospital, Liverpool, NSW, Australia., Sullivan J; University of new South Wales, Randwick, NSW, Australia.; Kingsway Dermatology and Aesthetics, Miranda, NSW, Australia.
Jazyk: angličtina
Zdroj: International journal of dermatology [Int J Dermatol] 2024 Oct 04. Date of Electronic Publication: 2024 Oct 04.
DOI: 10.1111/ijd.17501
Abstrakt: Evolving evidence suggests that Janus Kinase Inhibitors (JAKi) may predispose to certain infections, including tuberculosis and human herpes viruses. This review aimed to compare the infection risk in patients on a systemic JAKi for a dermatologic indication to a placebo. A systematic review was carried out from inception to June 2023, using the EMBASE, Medline, SCOPUS, and Cochrane Library of Registered Trials databases. Eligible studies included placebo-controlled randomized trials that investigated the incidence of infection in patients with a dermatologic indication. Primary outcomes included the most commonly reported infections pertaining to serious and opportunistic infections, upper respiratory tract infections, nasopharyngitis, herpes simplex, varicella zoster, tuberculosis, neutropenia, and lymphopenia. A meta-analysis of incidence ratios was conducted to determine odds ratios (OR), with a 95% confidence interval (CI) analysis. The meta-analysis found no increased risk of serious (OR: 0.92, 95% CI: 0.61-1.43, P = 0.74) or opportunistic infections (OR: 0.65, 95% CI: 0.32-1.31, P = 0.23). The incidence of varicella-zoster infections was significantly higher in the JAKi cohort (OR: 1.72, 95% CI: 1.08-2.72, P = 0.022). From 25 studies, there was no overall increased risk of herpes simplex infections (OR: 1.43, 95% CI: 0.93-2.23, P = 0.102) to placebo; however, a significantly higher risk in those with atopic dermatitis to alopecia areata was demonstrated (OR: 1.73, 95% CI: 1.13-2.69, P = 0.013). The results of this analysis do not suggest an increased risk of serious and opportunistic infections in those on JAKi compared to placebo. However, they support an increased risk of varicella-zoster infections and a higher risk of herpes simplex infections in those with atopic dermatitis to alopecia areata. The results of this report support these agents' short-term safety but signal that vigilance should be practiced in patients at risk for serious or recurrent herpes virus infections.
(© 2024 The Author(s). International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.)
Databáze: MEDLINE
Externí odkaz: